Markets:

Overview

News

Currencies

International

Treasuries

Corvus Pharmaceuticals, Inc. - Common Stock (NQ:CRVS)

12.08 -0.33 (-2.66%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corvus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 04, 2023

Via Benzinga

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

April 03, 2023

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 28, 2023

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Corvus Pharmaceuticals Earnings Preview ↗

March 27, 2023

Via Benzinga

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

March 21, 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence ↗

February 21, 2023

Via Benzinga

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

March 14, 2023

Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad...

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 21, 2023

Via Benzinga

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

February 21, 2023

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying ↗

December 21, 2022

The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More ↗

December 16, 2022

The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗

December 13, 2022

Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.

Via Benzinga

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

December 12, 2022

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

December 05, 2022

Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

November 14, 2022

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

November 03, 2022

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

November 03, 2022

Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Preview For Corvus Pharmaceuticals ↗

November 02, 2022

Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

October 27, 2022

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

October 25, 2022

From Corvus Pharmaceuticals, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022 ↗

October 07, 2022

Upgrades

Via Benzinga

10 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners ↗

October 05, 2022

In this article, we will be taking a look at some of the top stocks in the portfolio of Jeffrey Diehl.

Via Talk Markets

Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer ↗

September 27, 2022

Via Benzinga

Corvus Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Corvus Pharmaceuticals Q4 Earnings ↗

March 10, 2022

Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

A Preview Of Corvus Pharmaceuticals's Earnings ↗

March 09, 2022

Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....

Via Benzinga

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗

June 28, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday ↗

June 27, 2022

Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.